Bio-Rad Laboratories Inc.

5 days ago · businesswire.com

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum on Thursday, September 24, 2026, at 8:50 AM Eastern Time. A live webcast and subsequent replay of the event will be available in the Investor Relation.

11 days ago · seekingalpha.com

Bio-Rad Laboratories (BIO) remains a Buy, after my assessment of relevant corporate disclosures at the recent Wells Fargo Healthcare conference. Management targets long-term operating margins of 20%, with intermediate milestones in the mid-teens, outpacing consensus expectations. Margin drivers include cost rationalization, AI-driven efficiencies, and a shift toward higher-margin consumables revenue.

12 days ago · seekingalpha.com

Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

17 days ago · globenewswire.com

NEW YORK and TOKYO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC.

18 days ago · zacks.com

Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?

20 days ago · globenewswire.com

HOLMDEL, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), a global leader in Identity and Access Management and biometric authentication technologies, announced that its CEO Michael DePasquale will be available for virtual meetings at H.C.

21 days ago · businesswire.com

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Wells Fargo's 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM Eastern Time (12:45 PM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relati.

1 month ago · zacks.com

BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.

1 month ago · zacks.com

BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.

1 month ago · globenewswire.com

BIO-key's (BKYI)Bottom Line Improves 51% on 13% Rise in Q2 Revenues Reflecting Strength with Government, Defense, and Financial Sector Customers Globally.